Silipide
Alternative Names: IdB 1016Latest Information Update: 18 Apr 2011
At a glance
- Originator Inverni della Beffa
- Developer Indena; Inverni della Beffa
- Class Antivirals; Hepatoprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C; Liver disorders; Ovarian cancer
Most Recent Events
- 07 Oct 2004 Phase-II clinical trials in Ovarian cancer in Italy (PO)
- 06 Sep 1999 No-Development-Reported for Hepatitis C in Italy (PO)
- 30 Aug 1999 Sanofi and Synthélabo have merged to form Sanofi-Synthélabo